Vancouver, Canada, November 4th, 2025, FinanceWire Equity Insider News Commentary – The precision medicine sector reached ...

A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...

2. Mergers and acquisitions are picking up: So far this year, buyouts have boosted several biotech stocks. Some standouts: Regulus Therapeutics went up 120%; 89bio went up 85%; Chimerix gained 69% and ...

For many decades, since the discovery and exploration of oil in the Niger Delta of Nigeria, oil spillage has been a recurring health, ...

Veterans die by suicide at roughly a 50% higher rate than non-veterans. That's why, the American Foundation for Suicide Prevention (AFSP), a leading suicide prevention organization, launched Talk ...

Evaxion Biotech ( ($EVAX) ) has shared an update. On November 3, 2025, Evaxion A/S announced the expansion of its R&D pipeline with the ...

North America: Dominates the market due to advanced healthcare infrastructure, high breast cancer prevalence, and innovation-driven companies. The US alone is expected to reach USD 468.7 million by ...

Hong Kong Exchanges and Clearing (HKEX) will launch five new weekly stock options and a Hang Seng Biotech Index Futures ...

Viking Therapeutics is mispriced due to the successful but misunderstood clinical results of their oral GLP-1 treatment. Read ...

Firn says its active ingredient, derived from organisms dormant since the Ice Age, significantly increases skin’s natural capacity for self-regeneration.

Synthetic biology is ready for the next developmental milestone and America’s leadership depends on getting the financing right.